MM-102 is a novel potent inhibitor of MLL1/WDR5 protein-protein interaction.
CAT No: R1919
CAS No: 1417329-24-8
Synonyms/Alias: MM-102;1417329-24-8;HMTase Inhibitor IX;N-[bis(4-fluorophenyl)methyl]-1-[[(2S)-5-(diaminomethylideneamino)-2-[[2-ethyl-2-(2-methylpropanoylamino)butanoyl]amino]pentanoyl]amino]cyclopentane-1-carboxamide;CHEMBL3883592;SCHEMBL12035529;BDBM200723;MM102;(S)-N-(Bis(4-fluorophenyl)methyl)-1-(2-(2-ethyl-2-isobutyramidobutanamido)-5-guanidinopentanamido)cyclopentanecarboxamide;BCP11764;EX-A1503;s7265;AKOS030526507;CCG-270356;MM-102?;NCGC00351775-01;AC-36316;DA-65547;HY-12220;TS-09297;US9233086, 10L;SW220028-1;G14355;BRD-K68474068-001-01-8;cyclopentanecarboxamide, 1-[[(2S)-5-[(aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]-;N-[bis(4-fluorophenyl)methyl]-1-[(2S)-5-carbamimidamido-2-[2-ethyl-2-(2-methylpropanamido)butanamido]pentanamido]cyclopentane-1-carboxamide;
Chemical Name: N-[bis(4-fluorophenyl)methyl]-1-[[(2S)-5-(diaminomethylideneamino)-2-[[2-ethyl-2-(2-methylpropanoylamino)butanoyl]amino]pentanoyl]amino]cyclopentane-1-carboxamide
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C35H49F2N7O4 |
M.W/Mr. | 669.8 |
Appearance | Solid powder |
Biological Activity | MM-102 is a potent WDR5/MLL interaction inhibitor (IC50 = 2.4 nM). It has been shown to block MLL1 methyltransferase activity, reducing the expression of HoxA9 and Meis-1 genes, which are both critical MLL1 target genes in MLL1 fusion protein-mediated leukemogenesis. WD-repeat protein 5 (WDR5) is a scaffold protein commonly involved in the formation of nucleosome-modifying protein complexes with histones. |
Long-term Storage Conditions | Soluble in DMSO |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
InChI | InChI=1S/C35H49F2N7O4/c1-5-34(6-2,43-29(45)22(3)4)31(47)41-27(10-9-21-40-33(38)39)30(46)44-35(19-7-8-20-35)32(48)42-28(23-11-15-25(36)16-12-23)24-13-17-26(37)18-14-24/h11-18,22,27-28H,5-10,19-21H2,1-4H3,(H,41,47)(H,42,48)(H,43,45)(H,44,46)(H4,38,39,40)/t27-/m0/s1 |
InChI Key | RZKSQRIPRKWVBU-MHZLTWQESA-N |
Canonical SMILES | CCC(CC)(C(=O)NC(CCCN=C(N)N)C(=O)NC1(CCCC1)C(=O)NC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)NC(=O)C(C)C |
Isomeric SMILES | CCC(CC)(C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1(CCCC1)C(=O)NC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)NC(=O)C(C)C |
References | 1: Zhang Z, Zhai Y, Ma X, Zhang S, An X, Yu H, Li Z. Down-Regulation of H3K4me3 by MM-102 Facilitates Epigenetic Reprogramming of Porcine Somatic Cell Nuclear Transfer Embryos. Cell Physiol Biochem. 2018;45(4):1529-1540. doi: 10.1159/000487579. Epub 2018 Feb 16. PubMed PMID: 29466785. 2: Sun Z, Yu X, Chen W, Yang Q, Song Y, Zhou J, Jiang H. Costal Cartilage Assessment in Surgical Timing of Microtia Reconstruction. J Craniofac Surg. 2017 Sep;28(6):1521-1525. doi: 10.1097/SCS.0000000000003751. PubMed PMID: 28692518. 3: Weirich S, Kudithipudi S, Jeltsch A. Somatic cancer mutations in the MLL1 histone methyltransferase modulate its enzymatic activity and dependence on the WDR5/RBBP5/ASH2L complex. Mol Oncol. 2017 Apr;11(4):373-387. doi: 10.1002/1878-0261.12041. Epub 2017 Mar 10. PubMed PMID: 28182322; PubMed Central PMCID: PMC5527479. |
1. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
4. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.